If a Bear Market Is Coming, History Says These Stocks Could Be the Smartest to Own

The article presents Johnson & Johnson, Medtronic, Coca-Cola and Procter & Gamble as defensive dividend stocks to consider ahead of a potential bear market, citing their healthcare and consumer-staples businesses and long dividend records. Medtronic reported nearly 14% revenue growth in fiscal Q1 2027 and raised its full-year revenue and earnings targets; Coca-Cola's Q2 2026 organic sales rose 6% with case volume up 5%, while P&G's fiscal Q1 2027 organic sales increased 4%. Reported dividend yields range from 2% for J&J to 3% for Medtronic; the article notes that past sector resilience does not guarantee future performance.

Analysis

The useful signal is portfolio behavior, not the article’s dividend framing: JNJ, KO, MDT and PG may dampen earnings volatility in a slowdown, but they are not bond substitutes. If real yields rise, their dependable cash flows can still be discounted more heavily, compressing multiples even as operating results hold up. Defensive-stock crowding could also make the relative trade work better than an outright “safe haven” purchase.

Within the group, KO and PG depend on sustaining pricing and mix as consumers trade down; volume resilience matters more than headline organic sales. That creates substitution risk for branded goods and raises the value of monitoring unit volumes and promotional intensity. For JNJ and MDT, healthcare demand is less cyclical, but reimbursement, litigation and product execution can overwhelm that resilience. MDT’s product-growth case requires confirmation in adoption and recurring revenue, not just an upgraded near-term outlook. Healthcare competitors and suppliers may share demand tailwinds, but not necessarily the same margins or risks.

Over 1–3 months, watch real yields, consumer volumes, guidance revisions and device adoption; over 6–18 months, patent/reimbursement pressure and sustained pricing power matter more. The contrarian point: historical crisis outperformance does not establish attractive entry multiples or guarantee recovery leadership. Without valuation and relative-performance data, the article alone is not a catalyst for an outright overweight.

Key Decisions for Investors

• Consider a staged defensive relative-value position—long XLP/XLV versus SPY or a more cyclical equity basket—rather than treating these four stocks as downside protection. Size only after checking current valuation spreads and factor crowding; trim if defensives materially outperform while real yields rise.
• For individual exposure, wait for evidence that KO and PG sustain unit volumes without escalating promotions. A volume slowdown or guidance reduction would falsify the resilience thesis; sustained volume with stable pricing/mix would support adding exposure.
• Treat MDT’s growth narrative as a watch item: verify Hugo adoption, procedure growth and the next guidance update before paying for acceleration. Slowing growth or an outlook cut weakens the case; adoption without deterioration in margins would strengthen it.
• Do not infer low risk from JNJ’s diversification or dividend record. Monitor litigation outcomes, pharmaceutical patent exposure and device performance; adverse developments could outweigh defensive-sector flows.